Protocol ID93-008 
Page 16 
1 1.1.3 Written reports should be sent within 10 working days to: 
Investigational Drug Branch 
Cancer Therapy Evaluation Program 
P. O. Box 30012 
Bethesda, MD 20824 
and 
Office of Recombinant DNA Activities 
National Institutes of Health 
Building 31. Room 4B1 1 
Bethesda, MD 20892 
1 1. 1.4 All adverse reactions should be reported to the Institutional Review Board. 
[474] 
Recombinant DNA Research, Volume 19 
